What is Sunshine Biopharma's market cap?

Sunshine Biopharma (SBFM) has a market capitalization of $58.1K and trades on NASDAQ.

Who are Sunshine Biopharma's competitors?

Sunshine Biopharma's key competitors include Pfizer, Moderna, Merck & Co., and others. These companies compete in similar markets and product categories.

Who does Sunshine Biopharma partner with?

Sunshine Biopharma's notable partners include University of Arizona, WuXi AppTec, Amazon, and others.

What subsidiaries does Sunshine Biopharma have?

Sunshine Biopharma's subsidiaries include Nora Pharma Inc., Sunshine Biopharma Canada Inc..

Where is Sunshine Biopharma headquartered?

Sunshine Biopharma is headquartered in Canada and employs approximately 44 people. It has been publicly traded since 2007.

Sunshine Biopharma (SBFM) Stock Fundamentals & Financials

Sunshine Biopharma is a pharmaceutical company focused on the commercialization of generic prescription drugs and the research and development of proprietary medicines in oncology and antivirals.

Market cap

$58.06K-99.3%

Earnings

Q2 2026 report

August 13, 2026

Revenue$9.3MBeat by $563.7K EPS-$1.15Beat by $0.05

Read the full report

Next report

Nov 12, 2026 (in a month)

Revenue estimate$9.6M

EPS estimate-$0.17

Competitors

By market cap

Eli Lilly$1.04T+36.0%

Merck & Co.$351.28B+60.7%

Gilead Sciences$182.40B+25.9%

Pfizer$158.56B+10.5%

Bristol-Myers Squibb$121.70B+33.8%

Moderna$78.6B+634%

Cosmos Holdings Inc.$31.6M-7.3%

Sunshine Biopharma$58.1K-99.2%

By revenue growth

Eli Lilly+49.6%

Gilead Sciences+5.5%

Merck & Co.+4.6%

Bristol-Myers Squibb+3.1%

Pfizer-0.2%

Moderna-27.6%

By net margin

Eli Lilly33.53%+7.6pp

Bristol-Myers Squibb18.87%+8.4pp

Pfizer15.65%+1.6pp

Merck & Co.4.77%-21.0pp

Gilead Sciences-10.64%-32.5pp

Moderna-141.43%-47.1pp

Profile

Sunshine Biopharma is a pharmaceutical company focused on the commercialization of generic prescription drugs and the research and development of proprietary medicines in oncology and antivirals. The company operates a portfolio of over 70 generic medications in Canada while advancing a pipeline of mRNA-based cancer treatments and small molecule protease inhibitors for viral infections. Its value proposition centers on providing affordable, high-quality generic alternatives and developing first-in-class therapies for unmet medical needs.

Competitive position

A rapidly growing challenger in the Canadian generic market with a specialized focus on high-barrier therapeutic areas like oncology and antivirals.

GeographiesCanada, United States

Customer segmentsRetail Pharmacies, Government Health Agencies, Direct-to-Consumer

Business modelManufacturing and Distribution, Research and Development, Licensing

SuppliersInternational generic drug manufacturers, Lipid nanoparticle (LNP) technology providers, Contract manufacturing organizations (CMOs), Academic research institutions

CustomersRetail pharmacy chains, Public drug plans, Hospital networks, E-commerce consumers

CountryCanada

Listed2007

Employees44.0

CEOSteve N. Slilaty

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitesunshinebiopharma.com

FilingsSEC EDGAR

FAQ

What is Sunshine Biopharma's market cap?: Sunshine Biopharma (SBFM) has a market capitalization of $58.1K and trades on NASDAQ.
Who are Sunshine Biopharma's competitors?: Sunshine Biopharma's key competitors include Pfizer, Moderna, Merck & Co., and others. These companies compete in similar markets and product categories.
Who does Sunshine Biopharma partner with?: Sunshine Biopharma's notable partners include University of Arizona, WuXi AppTec, Amazon, and others.
What subsidiaries does Sunshine Biopharma have?: Sunshine Biopharma's subsidiaries include Nora Pharma Inc., Sunshine Biopharma Canada Inc..
Where is Sunshine Biopharma headquartered?: Sunshine Biopharma is headquartered in Canada and employs approximately 44 people. It has been publicly traded since 2007.